Medicine Matters rheumatology

Welcome

We provide news, expert interviews, and educational resources to help you keep up with the latest developments in rheumatology

Learn more

New additions to the Adis Journal Club – October update

Browse October's selection of peer-reviewed articles from the Adis journal portfolio. Curated by the editors and updated monthly. These papers highlight topical research and reviews for the benefit of Medicine Matters readers.

News

Study identifies sex differences in RA remission rates

Men with rheumatoid arthritis initiating treatment with biologic or targeted synthetic DMARDs may be more likely to achieve remission than women, research suggests. Read more

Have the ORAL Surveillance results changed rheumatology practice?

Following publication of the ORAL Surveillance trial, Richard Conway and Kevin Winthrop discuss the impact of the findings on JAK inhibitor prescribing, how regulatory recommendations compare in Europe and the USA, and whether the risks seen with tofacitinib represent a class effect.

Pain intensity correlates with disease activity in RA

SGLT2 inhibitors linked to lower gout risk than DPP-4 inhibitors

Elevated risk for osteoporotic fractures in women with SSc

Study identifies sex differences in RA remission rates

Reduced-dose hydroxychloroquine linked to higher flare risk in SLE

Study questions long-term benefits of recurrent intra-articular steroid injections

View all latest news

IN FOCUS | JAK inhibitors

30-09-2022 | Rheumatoid arthritis | News

Study identifies sex differences in RA remission rates

Men with rheumatoid arthritis initiating treatment with biologic or targeted synthetic DMARDs may be more likely to achieve remission than women, suggests research reported at The Lancet Summit: Sex and gender in rheumatology.

Study identifies sex differences in RA remission rates

EMA recommends approval of upadacitinib for nonradiographic axSpA

Targeted therapy not linked to serious infection risk in older people with RA

Call for CV risk assessment when starting tofacitinib in patients with PsA

Deucravacitinib warrants further investigation for SLE

Mixed results for MACE risk with JAK inhibitors in RA

IN FOCUS | COVID-19 & rheumatic disease

30-08-2022 | COVID-19 | News

Studies bolster evidence for COVID-19 vaccination in young people with RMDs

Findings from three studies provide further support for the effectiveness and safety of COVID-19 vaccines in young people with rheumatic and musculoskeletal diseases.

IN FOCUS | Inflammatory arthritis

08-09-2022 | Axial spondyloarthritis | News

Pregnancy outcome data ‘reassuring’ for women with axSpA

Women with axial spondyloarthritis have “very low” rates of adverse pregnancy outcomes, show observational data from European pregnancy registries.

Pain intensity correlates with disease activity in RA

SGLT2 inhibitors linked to lower gout risk than DPP-4 inhibitors

Successful retreatment of axSpA flare feasible following ixekizumab withdrawal

Study identifies risk factors for mortality in RA-ILD

Gout risk factor prevalence may explain increased rates among Black Americans

Methotrexate side effects more common in PsA than RA

IN FOCUS | Gout and crystal arthropathies

04-08-2022 | Gout | News

Gout flares linked to temporary increase in cardiovascular risk

Gout flares are associated with an increased risk for cardiovascular events in the following 120 days, study findings suggest.

SGLT2 inhibitors linked to lower gout risk than DPP-4 inhibitors

Local environment impacts recurrent hospitalization risk in rheumatic disease

Gout risk factor prevalence may explain increased rates among Black Americans

Gout flares linked to temporary increase in cardiovascular risk

Study highlights sex-specific CVD risks in men with gout

Topical alkalinizing treatment shows potential for acute gout

IN FOCUS | Lupus

01-09-2022 | Cardiovascular disease | News

CV risk reduction should be ‘an integral part’ of autoimmune disease management

A large study published in The Lancet has found that people with autoimmune diseases have an approximately 1.4–3.6-fold increased risk for developing cardiovascular disease relative to the general population.

Reduced-dose hydroxychloroquine linked to higher flare risk in SLE

Local environment impacts recurrent hospitalization risk in rheumatic disease

Male sex, older age risk factors for acute kidney abnormalities in childhood SLE

Childhood adiposity link to PsA, SLE risk ‘may not be fully reversible’

Different SLE targets independently linked to reduced damage accrual

CV risk reduction should be ‘an integral part’ of autoimmune disease management

Stay informed with Medicine Matters

Get the latest developments in rheumatology delivered straight to your inbox

Image Credits

Medicine Matters branded image/© Springer Healthcare, Rheumatology & Therapy, Doctor holds a two puzzle pieces with gender symbols/© wladimir1804 / stock.adobe.com, Richard Conway and Kevin Winthrop, Adis Journal Club, Magnifying glass and laptop/© Michail_Petrov-96 / Getty Images / iStock, Close up of a teenage girl wearing a mask being vaccinated/© © klavdiyav / stock.adobe.com, Covid-19 antigen self-tests positive, buffer bottles and thin black-rimmed glasses/© Kira / stock.adobe.com, Antibodies, immunoglobulin proteins, Immune system. 3D rendering/© Gilnature / Getty Images / iStock, Covid-19 vaccine vial and needle close up/© Leigh Prather / stock.adobe.com, Vector illustration of two profiles with speech bubbles inside their heads - debate concept/© JakeOlimb / Getty Images / iStock, IV drip/© © Trsakaoe / stock.adobe.com, Pregnant woman sitting on bed with hands on belly - pregnancy, parenthood, preparation and expectation concept./© NataliaDeriabina / Getty Images / iStock, Doctor and calculator/© nito / stock.adobe.com, Man with painful and swollen right foot due to gout inflammation/© ThamKC / stock.adobe.com, Febuxostat and CV risk signpost image/© hriana / stock.adobe.com, Clogged Artery, Arteriosclerosis Cholesterol plaque. 3d illustration/© Mohammed Haneefa Nizamudeen / Getty Images / iStock, Anifrolumab for the treatment of lupus/© ustas / stock.adobe.com, New Content Item/© bloomicon / stock.adobe.com